Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 1
1985 2
1988 4
1989 2
1990 2
1991 1
1992 2
1993 2
1994 4
1995 1
1997 2
1998 2
1999 2
2002 2
2003 1
2004 7
2005 3
2006 7
2007 5
2008 2
2009 3
2010 2
2011 4
2012 4
2013 7
2014 9
2015 3
2016 10
2017 19
2018 14
2019 21
2020 31
Text availability
Article attribute
Article type
Publication date

Search Results

172 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Clinical significance of monocyte heterogeneity.
Stansfield BK, Ingram DA. Stansfield BK, et al. Clin Transl Med. 2015 Feb 14;4:5. doi: 10.1186/s40169-014-0040-3. eCollection 2015. Clin Transl Med. 2015. PMID: 25852821 Free PMC article.
"Classical" monocytes express surface markers denoted as CD14(++)CD16(-) and account for greater than 70% of total monocyte count, while "non-classical" monocytes express the CD16 antigen with low CD14 expression (CD14(+)CD16(++)). However, recognition of an …
"Classical" monocytes express surface markers denoted as CD14(++)CD16(-) and account for greater than 70% of total monocyte co …
The Endless Saga of Monocyte Diversity.
Canè S, Ugel S, Trovato R, Marigo I, De Sanctis F, Sartoris S, Bronte V. Canè S, et al. Front Immunol. 2019 Aug 6;10:1786. doi: 10.3389/fimmu.2019.01786. eCollection 2019. Front Immunol. 2019. PMID: 31447834 Free PMC article. Review.
There are several cellular and molecular mechanisms at play, and the goal is to identify those that are clinically significant. Among the hematopoietic-derived cells, monocytes are endowed with high plasticity, responsible for their pro- and anti-tumoral func …
There are several cellular and molecular mechanisms at play, and the goal is to identify those that are clinically significant
Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O, Szladovits B, Polton G, Garden OA, Leo C, Lara-Garcia A. Davies O, et al. Vet Comp Oncol. 2018 Jun;16(2):276-287. doi: 10.1111/vco.12378. Epub 2017 Dec 22. Vet Comp Oncol. 2018. PMID: 29271043
Canine lymphoma is a heterogeneous group of diseases and many previous studies have evaluated the response of a mixed population of lymphoma cases to one specific treatment protocol. ...Median overall survival (OS) was 322 days, the 1-year survival rate was 38% and the 2-y …
Canine lymphoma is a heterogeneous group of diseases and many previous studies have evaluated the response of a mixed population of l …
Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease.
Maguire EM, Pearce SWA, Xiao Q. Maguire EM, et al. Vascul Pharmacol. 2019 Jan;112:54-71. doi: 10.1016/j.vph.2018.08.002. Epub 2018 Aug 14. Vascul Pharmacol. 2019. PMID: 30115528 Review.
Indeed several GWAS and animal studies have identified key genes and proteins required for monocyte recruitment as well cholesterol handling involving lipid uptake, cholesterol esterification and cholesterol efflux. ...Finally, studies targeting each aspect of foam cell fo …
Indeed several GWAS and animal studies have identified key genes and proteins required for monocyte recruitment as well cholesterol h …
Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals.
Georgakis MK, Malik R, Björkbacka H, Pana TA, Demissie S, Ayers C, Elhadad MA, Fornage M, Beiser AS, Benjamin EJ, Boekholdt SM, Engström G, Herder C, Hoogeveen RC, Koenig W, Melander O, Orho-Melander M, Schiopu A, Söderholm M, Wareham N, Ballantyne CM, Peters A, Seshadri S, Myint PK, Nilsson J, de Lemos JA, Dichgans M. Georgakis MK, et al. Circ Res. 2019 Sep 27;125(8):773-782. doi: 10.1161/CIRCRESAHA.119.315380. Epub 2019 Sep 3. Circ Res. 2019. PMID: 31476962 Free PMC article.
Experimental evidence and Mendelian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis and stroke. ...Conclusions: Higher circulating levels of MCP-1 are associated with increased long-term risk of stroke. Our findings along with …
Experimental evidence and Mendelian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis and …
NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
Berry JD, Cudkowicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, McKenna-Yasek D, Levy YS, Abramov N, Kaspi H, Mehra M, Aricha R, Gothelf Y, Brown RH. Berry JD, et al. Neurology. 2019 Dec 10;93(24):e2294-e2305. doi: 10.1212/WNL.0000000000008620. Epub 2019 Nov 18. Neurology. 2019. PMID: 31740545 Free PMC article. Clinical Trial.

In a prespecified rapid progressor subgroup (n = 21), rate of disease progression was improved at early time points (p < 0.05). To address heterogeneity, a responder analysis showed that a higher proportion of treated participants experienced 1.5 points/month ALSFRS-R s

In a prespecified rapid progressor subgroup (n = 21), rate of disease progression was improved at early time points (p < 0.05). To addres

Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.
Beke A, Laplane L, Riviere J, Yang Q, Torres-Martin M, Dayris T, Rameau P, Saada V, Bilhou-Nabera C, Hurtado A, Lordier L, Vainchenker W, Figueroa ME, Droin N, Solary E. Beke A, et al. Haematologica. 2020 Jan;105(1):112-123. doi: 10.3324/haematol.2018.208488. Epub 2019 May 2. Haematologica. 2020. PMID: 31048357 Free PMC article.
CD34(+) cells from an age-matched healthy donor were also reprogrammed. We captured a part of the genetic heterogeneity observed in the patient, i.e. we analyzed five clones with two genetic backgrounds, without and with the KRAS(G12D) mutation. ...These anal …
CD34(+) cells from an age-matched healthy donor were also reprogrammed. We captured a part of the genetic heterogeneity observ …
Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume-to-Platelet Count Ratio as Biomarkers in Critically Ill and Injured Patients: Which Ratio to Choose to Predict Outcome and Nature of Bacteremia?
Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, Zeba S, Milosavljevic S, Stankovic N, Abazovic D, Jevdjic J, Vojvodic D. Djordjevic D, et al. Mediators Inflamm. 2018 Jul 15;2018:3758068. doi: 10.1155/2018/3758068. eCollection 2018. Mediators Inflamm. 2018. PMID: 30116146 Free PMC article.
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume-to-platelet count (MPV/PC) ratio are readily available parameters that might have discriminative power regarding outcome. ...F …
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and mean pl …
Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer.
Mony JT, Schuchert MJ. Mony JT, et al. Front Immunol. 2018 Oct 15;9:2298. doi: 10.3389/fimmu.2018.02298. eCollection 2018. Front Immunol. 2018. PMID: 30374348 Free PMC article.
Background: Studies in the past have identified selected immune cells that associate with different clinical outcomes in non-small cell lung cancer (NSCLC). Considering the fact that immune responses are heterogenous and that the clinical outcome could be inf …
Background: Studies in the past have identified selected immune cells that associate with different clinical outcomes in non-small ce …
Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF, Hasserjian RP, Aggarwal N, Seegmiller AC, Pozdnyakova O. Mason EF, et al. Blood Adv. 2019 Nov 12;3(21):3322-3332. doi: 10.1182/bloodadvances.2019000328. Blood Adv. 2019. PMID: 31698462 Free PMC article.
AML with mutated NPM1 (AML-NPM1) represents a distinct entity in the revised 2017 World Health Organization classification, but relatively little work has examined the clinical significance of phenotypic and genetic heterogeneity within this group. A m …
AML with mutated NPM1 (AML-NPM1) represents a distinct entity in the revised 2017 World Health Organization classification, but relatively l …
172 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback